ATE295170T1 - Verwendung von einem antagonist der zentralen kannabinoidrezeptoren zur herstellung von arzneimitteln - Google Patents

Verwendung von einem antagonist der zentralen kannabinoidrezeptoren zur herstellung von arzneimitteln

Info

Publication number
ATE295170T1
ATE295170T1 AT00966200T AT00966200T ATE295170T1 AT E295170 T1 ATE295170 T1 AT E295170T1 AT 00966200 T AT00966200 T AT 00966200T AT 00966200 T AT00966200 T AT 00966200T AT E295170 T1 ATE295170 T1 AT E295170T1
Authority
AT
Austria
Prior art keywords
antagonist
production
medicinal products
cannabinoid receptors
central cannabinoid
Prior art date
Application number
AT00966200T
Other languages
English (en)
Inventor
Bernard Bourrie
Pierre Casellas
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE295170T1 publication Critical patent/ATE295170T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
AT00966200T 1999-10-01 2000-09-27 Verwendung von einem antagonist der zentralen kannabinoidrezeptoren zur herstellung von arzneimitteln ATE295170T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9912415A FR2799124B1 (fr) 1999-10-01 1999-10-01 Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
PCT/FR2000/002662 WO2001024798A1 (fr) 1999-10-01 2000-09-27 Utilisation d'un antagoniste des recepteurs aux cannabinoïdes centraux pour la preparation de medicaments

Publications (1)

Publication Number Publication Date
ATE295170T1 true ATE295170T1 (de) 2005-05-15

Family

ID=9550596

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00966200T ATE295170T1 (de) 1999-10-01 2000-09-27 Verwendung von einem antagonist der zentralen kannabinoidrezeptoren zur herstellung von arzneimitteln

Country Status (12)

Country Link
US (1) US6642258B1 (de)
EP (1) EP1221952B1 (de)
JP (1) JP2003510361A (de)
AR (1) AR025883A1 (de)
AT (1) ATE295170T1 (de)
AU (1) AU7667300A (de)
DE (1) DE60020145T2 (de)
DK (1) DK1221952T3 (de)
ES (1) ES2240176T3 (de)
FR (1) FR2799124B1 (de)
PT (1) PT1221952E (de)
WO (1) WO2001024798A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535349A (en) 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
WO2006060192A2 (en) * 2004-11-30 2006-06-08 Bayer Pharmaceuticals Corporation Pyrazole derivatives
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2007084450A2 (en) 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
WO2009005646A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
WO2009021106A1 (en) * 2007-08-07 2009-02-12 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
AR025883A1 (es) 2002-12-18
PT1221952E (pt) 2005-08-31
DE60020145D1 (de) 2005-06-16
JP2003510361A (ja) 2003-03-18
WO2001024798A1 (fr) 2001-04-12
AU7667300A (en) 2001-05-10
ES2240176T3 (es) 2005-10-16
DK1221952T3 (da) 2005-08-29
DE60020145T2 (de) 2006-02-16
FR2799124B1 (fr) 2004-08-13
US6642258B1 (en) 2003-11-04
EP1221952A1 (de) 2002-07-17
FR2799124A1 (fr) 2001-04-06
EP1221952B1 (de) 2005-05-11

Similar Documents

Publication Publication Date Title
DE60020145D1 (de) Verwendung von einem antagonist der zentralen kannabinoidrezeptoren zur herstellung von arzneimitteln
DE60017336D1 (de) Zusammensetzung zur Herstellung von Harzen
ATE358480T1 (de) Verwendung von antagonisten der zentralen kannabinoidrezeptoren zur regulierung von suchterscheinungen
ATE283264T1 (de) Zwischenprodukte zur herstellung von metallproteinasehemmern
DE69937076D1 (de) Zwischenprodukte für die Herstellung von Imidazo-Pyridin-Derivate
DE69834437D1 (de) Verfahren zur Herstellung von Fenofibrathaltigen Arzneizusammensetzungen mit erhöhter Bioverfügbarkeit
DE60008315D1 (de) Verfahren zur Herstellung von Methylchlorid
ATE308525T1 (de) Hydantoin-, thiohydantoin-, pyrimidinedion- und thioxopyrimidinon-derivate, verfahren zur ihrer herstellung und ihre anwendung als arztneimittel
DE69712610D1 (de) Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel
DE50001027D1 (de) Verfahren zur Herstellung von substituierten Olefinen
DE60024960D1 (de) Kontinuierliches Verfahren zur Herstellung von Siliconharzen
DE69618607D1 (de) Derivate von 5-0-desosaminyl-6-0-methyl erythronolid a, ihre verfahren zur herstellung und verwendung zur herstellung von arzneimitteln
DE50007165D1 (de) Verfahren zur kontinuierlichen Herstellung hochviskoser füllstoffhaltiger Siliconmassen
ATE301645T1 (de) Polycyclische thiazolidin-2-yliden amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69822711D1 (de) Verfarhen zur Herstellung von Dialkylnaphthalinen
ID30484A (id) Turunan 4-heterosikliksulfonamidil 6 metoksi 5 (2 metoksi fenoksi) 2 piridil-pirimidin, pembuatannya dan penggunaan sebagai antagonis reseptor endotelin
DE69818698D1 (de) Inhibitoren von metalloproteinasen, ihre therapeutische verwendung und verfahren zur herstellung der grundstoffe für ihre synthese
ATE295175T1 (de) Verwendung von unverseifbaren pflanzlichen ölen für die herstellung pharmazeutischer präparate
DE60002870D1 (de) Epoxybeschichtete mehrschichtstrukturen für die verwendung in der herstellung von sicherheitsdokumenten
FI953720A7 (fi) Neurotensiiniantagonistien käyttö diureettietan lääkkeiden valmistamiseksi
DE50212938D1 (de) Derivate von c2-substituierten indan-1-ol-systemen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE60019763D1 (de) Verfahren zur herstellung von thiazolderivaten
DE50006821D1 (de) Die verwendung von tricyclodecandimethanol zur herstellung von mehrschichtlackierungen
DE60043559D1 (de) Verfahren zur Herstellung von Elektroden
DE69931316D1 (de) Verwendung von Aryl-Cyclohexylamine Derivaten zur Herstellung von NMDA-Rezeptorblockern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1221952

Country of ref document: EP

REN Ceased due to non-payment of the annual fee